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Background: Chest complaints presented to a general practitioner (GP) are frequently caused by diseases which
have advantageous outcomes. However, in some cases, acute coronary syndrome (ACS) is present (1.5-22% of cases).
The patient’s signs, symptoms and electrocardiography results are insufficient diagnostic tools to distinguish mild disease
from ACS. Therefore, most patients presenting chest complaints are referred to secondary care facilities where ACS is
then ruled out in a majority of patients (78%). Recently, a point of care test for heart-type fatty acid-binding
protein (H-FABP) using a low cut-off value between positive and negative of 4 ng/ml has become available. We
aim to study the role of this point of care device in triage of patients presenting chest complaints possibly due to
ACS, in primary care. Our research protocol is presented in this article. Results are expected in 2015.
Methods/Design: Participating GPs will register signs and symptoms in all patients presenting chest complaints
possibly due to ACS. Point of care H-FABP testing will also be performed. Our study will be a derivation study
to identify signs and symptoms that, combined with point of care H-FABP testing, can be part of an algorithm
to either confirm or rule out ACS. The diagnostic value for ACS of this algorithm in general practice will be determined.
Discussion: A safe diagnostic elimination of ACS by application of the algorithm can be of significant clinical relevance.
Improved triage and thus reduction of the number of patients with chest complaints without underlying ACS, that are
referred to secondary care facilities, could lead to a substantial cost reduction.
Trial registration: ClinicalTrials.gov, NCT01826994, accepted April 8th 2013.
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Daily practice
Patients presenting with chest complaints caused by
acute coronary syndrome (ACS) need urgent transport
to a specialist setting [1,2]. In these situations, favourable
outcome is inversely related to the time interval be-
tween onset of complaints and vascular rescue treatment.
However, in daily practice, most patients experiencing
chest complaints primarily apply to a general practitioner
(GP). Within this population, benign conditions such as
thoracic wall complaints, gastric disease or psychiatric
and somatoform disease, largely outnumber cases of ACS
[3-5]. In specialised care facilities such as coronary care
units, 50% of patients presenting with chest pain are diag-
nosed with ACS, whereas in primary care, ACS is diag-
nosed in no more than 1.5-22% of cases [6-8]. Referring
every patient with chest complaints would overwhelm sec-
ondary care facilities, however the GP is faced with serious
diagnostic dilemmas since milder diseases with beneficial
outcome can mimic ACS and vice versa [9]. Safe exclusion,
rather than inclusion, is the main task of a GP in assessing
chest complaints.
In primary care, where clearly circumscribed diseases
with specific symptoms are embedded in a broad scope
of illness and mild disease with less typical appearance,
discriminative signs are usually scarce. This applies in
particular to ACS, where history, physical examination
and electrocardiography notoriously lack sensitivity and
specificity as has been extensively surveyed [10-12].
With regard to chest pain, only few signs and symptoms,
for example, the absence of pain on chest palpation or
presence of pain on exertion, generate discriminative
strength in diagnostic studies, although to a limited ex-
tent [9,13,14]. Altogether, clinical signs and symptoms
are inappropriate for ruling out ACS or lack additive
value above the clinical judgment by the GP, which on it-
self is correct in a majority of cases [6]. Weighing more
abstract factors (e.g. contextual patient factors and al-
tered presentation in time) probably leads to this fairly
adequate clinical judgment of GPs [15-17].
Because of these diagnostic problems in primary care,
most patients presenting complaints possibly matching
ACS are still referred to a cardiologist [18]. A low
threshold for referring patients with chest complaints to
secondary care is an effective strategy for the GP to avert
missed cases of ACS [19]. In the Netherlands, this strat-
egy results in 78% of referred patients that are ACS nega-
tive in the emergency room (positive predictive value
(PPV) is 22%), whereas ACS is present in 5% of patients
that are not referred (negative predictive value (NPV) is
95%) and the outcome is probably not severely affected
by initially not referring (specificity and sensitivity of
clinical assessment by GP: 55%, resp 81%) [6,20]. To en-
hance triage by a GP and reduce patient burden insecondary care, new diagnostic tools should become avail-
able [21]. Combined with signs and symptoms, such tools
should be able to safely rule out ACS in a significant num-
ber of otherwise referred patients, without a rise in missed
cases of ACS. Importantly, this would lead to a significant
cost reduction. The number of referred patients would de-
crease and in the remaining patients who are referred,
ACS could be confirmed or ruled out as common in sec-
ondary care.
In the field of pulmonary embolism and respiratory
tract infections, diagnostic tools combining clinical signs
and symptoms with the result of a point of care (PoC)
test have recently been introduced. Both increased effi-
ciency by either reducing unnecessary referral (in cases
of suspected pulmonary embolism) or treatment (in re-
spiratory tract infections) [22-24]. For ACS, a similar
procedure has not yet been defined.
Biomarkers and point of care testing in primary care
Cardiac troponin T or I (cTnT or cTnI) measurement
has become the cornerstone of diagnosing acute myocar-
dial infarction (AMI) [25-29]. Some promising novel
biomarkers have featured in recent literature, for ex-
ample, copeptin and heart-type fatty acid-binding pro-
tein (H-FABP) [30-32]. Adding measurements of these
markers to troponin in an early phase in emergency
room settings increases sensitivity for ACS, but so far
the combination has failed to safely rule out ACS in an
early stage [33,34]. Until recently, troponin assays have
gained sensitivity due to usage of highly sensitive tech-
niques, referred to as high sensitive cardiac troponin
(hs-cTn). The additional value of H-FABP testing besides
hs-cTn is unclear [35,36]. At this moment, studies
reviewing early PoC markers are characterised by meth-
odological imperfections [37]. The function of H-FABP
and other early markers combined with signs and symp-
toms in risk classification in a low prevalence setting
such as primary care is still to be determined [38-40].
An earlier study in primary care evaluating a PoC-test
on H-FABP did not lead to implementation of PoC-
testing in daily practice because of a lack of NPV [20].
However, the PoC device for H-FABP used in this study
used a cut-off value of 7 ng/ml, which is above the 99th
percentile of 5.7 ng/ml as found in a normal reference
population [41]. Retrospective measurement of plasma
H-FABP values revealed added value of H-FABP, al-
though insufficient to reach a NPV of 98% or more. Re-
cently, a potential gain in sensitivity for PoC-testing has
been found by lowering the cut-off value to 4 ng/ml in a
secondary care population, where 50% of patients were
diagnosed with AMI [8]. Setting the cut-off value at
4 ng/ml leads to a diagnostic performance equalling that
of hs-cTn. Calculated NPV in a primary care population
(with an incidence of ACS of 20% or less) would reach
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than 3 hours and 97.9% in patients with a duration of
complaints of 3–24 hours.
When H-FABP-testing is combined with signs and
symptoms in a diagnostic algorithm, NPV hypothetically
improves and thus the number of patients that are re-
ferred by a GP but turn out to have no ACS, could be
reduced. Even with a moderate amount of false positive
results, such an algorithm could improve daily practice
since currently, the majority of patients without under-
lying ACS are referred to secondary care facilities. Thus,
our hypothesis is that net reduction of referral rate –
without an increase in missed cases of ACS – in patients
presenting chest complaints to their GP could be accom-
plished by the aforementioned algorithm including PoC
H-FABP-testing. Therefore a PoC H-FABP-device meet-
ing the demand of a lower cut-off value of 4 ng/ml has
recently been developed by FABPulous B.V. We intend
to study the diagnostic value of this device in primary
care. The methodology of the study is presented in the
remainder of this article in order to inform colleagues
in the same research field, to anticipate forthcoming re-
sults of our study and to prevent publication bias or
violation of the protocol during the running time of the
study.
Study design and objectives
This current study is a derivation study to identify signs
and symptoms that, combined with point of care heart-
type fatty acid-binding protein (PoC H-FABP) testing,
can be part of an algorithm to confirm or rule out ACS
(meaning AMI and unstable angina (UA)) and AMI
alone in a population of patients with complaints possibly
due to myocardial ischaemia in general practice. Thus,
stage 2 of the 6 major stages in the development and test-
ing of a clinical decision rule as defined by Stiell and Wells
will be studied [42]. The diagnostic value of the algorithm
will be studied and compared to regular assessment by a
GP without PoC H-FABP testing using a delayed type
cross-sectional diagnostic model. Both ACS and AMI as a
subgroup of ACS will be analysed as final diagnosis. The
cost-effectiveness of the test will also be evaluated. The
study commenced in November 2013 and will run for two
years. External validation of the algorithm derived from
this study needs to be performed in future studies.
Methods
Recruitment
Two hundred and ten GPs in four regions in the South
and Southeast of the Netherlands and the Northeast of
Belgium, including both urban and rural areas, will be
informed by e-mail of our study and given the opportun-
ity to respond. The first 60 GPs that decide to partici-
pate will receive a detailed training in using the test andperforming all relevant research activities in order to in-
clude ten successive eligible patients, making a total of
600 patients. Inclusion will take place at any time during
the day and night, including either during consultation
in a primary care facility or during home visits by par-
ticipating GPs. During evaluations in the study period
with participating GP’s, adherence to the protocol and
actual recruitment of consecutive cases will be checked
and reported.
Inclusion and exclusion criteria
Patients presenting to the GP with any new-onset chest
pain or pressure (ventral, dorsal and/or lateral), any left
or right upper arm pain or any pain in the epigastric,
neck or jaw region, at time of presentation not lasting
for more than 24 hours, that is considered to be of pos-
sible cardiac origin by the GP will be included. Patients
presenting burning sensation on the chest not typical for
gastric reflux or anxiety with referral to the chest region
are also eligible.
Patients presenting other, less specific complaints pos-
sibly matching ACS (dyspnoea, nausea, fatigue, etc.) will
only be included if at least one of the above mentioned
complaints of pain is co-presenting. Patients will be
excluded if an obvious emergency is present (haemo-
dynamic instability, otherwise severely ill patient, etc.).
Patients will be excluded if symptoms are present for
more than 24 hours, if written informed consent is re-
fused during presentation or withdrawn afterwards, if a
traumatic cause is present, if complaints are presented
that can be regarded as a recurrence of earlier complaints
with clear diagnosis (hyperventilation, stable angina) or in
case of death of unidentified cause.
Data collection
Eligible patients will be evaluated by the GP using the
following work up schedule:
1. The GP asks written informed consent using a short
version of the consent document in the Netherlands
or oral informed consent in Belgium.
2. The GP uses the standardised case report form
(CRF-HA) for documentation of history and
physical examination. If available and if considered
as indicated by the GP, an electrocardiogram (ECG)
is performed and documented by the GP.
3. The GP is instructed to fill out the presumptive
diagnosis together with the decision whether or
not to refer to a cardiologist, before performing
the H-FABP test.
4. The GP obtains one drop of blood from the patient’s
finger and starts the PoC H-FABP test. While the test
is running, the GP replaces the test in its cardboard
package.
Willemsen et al. BMC Family Practice 2014, 15:203 Page 4 of 8
http://www.biomedcentral.com/1471-2296/15/2035. At this moment, the GP should wait for no less and
no longer than 5 minutes before taking the device
out of the package again and reading the result. If
the GP is still working on point 1–3 as mentioned
above in the 5 minutes waiting time, he cannot be
influenced by discolouration of the test.
6. Five minutes after starting the test the result is
read. The result has to be added to the CRF-HA
directly.
By filling out the presumptive diagnosis together with
the decision whether or not to refer to a cardiologist
on the CRF-HA before reading the result of the PoC
H-FABP-test, the regular decision by the GP whether
or not to refer to a cardiologist, which is not influ-
enced by the test result, will be formally recorded.
Thus, we will be able to compare this regular care with
an algorithm using standardised signs and symptoms
with PoC H-FABP-testing. This procedure is seen as the
next-best option after complete blinding participating
GPs for the test result, which is impossible to realise
as test results must be read at the point of care within
5 minutes.
GPs will be instructed to base their referral decisions
on the current guidelines on ACS, as is common in the
Netherlands and Belgium [43]. Participating GPs will be
informed that the PoC H-FABP test is currently under
study and that the test results should not influence their
decision to refer. Only in the few cases that a PoC H-
FABP test is positive after an initial decision not to refer,
referral policy will be different from usual care since in
that rare occasion, the GP is advised to refer. By follow-
ing the registration work up as mentioned above, we can
still conclude that principally, a referral wouldn’t have
been made.
Patients that are not referred to secondary care will be
instructed and facilitated to have a venous blood sample
drawn within the interval between three hours to three
days after onset of complaints. Test results will be pri-
marily used to exclude AMI in non-referred patients
based on hsTn analysis. However, the GP is instructed to
take notice of the result. If the troponin value is elevated,
referral to a cardiologist must take place. Furthermore,
renal function, based on creatinine and glomerular filtra-
tion rate using MDRD-formulas, will be determined.
Collected samples will be preserved for a maximum of
15 years for possible future analysis when relevant.
Final diagnosis
The participating GP will send the CRF-HA (and ECG,
if present) to the research team. The research team will
contact the GP and, if referral has taken place and if ne-
cessary, the hospital, 30 days after inclusion to collect all
relevant patient data. Final diagnosis will be establishedby an expert panel of one independent GP and one
independent cardiologist, based on the outcome defi-
nitions. If agreement is not reached within the panel,
extension will automatically take place to a panel of
two cardiologists and two GPs. The expert panel will
be blinded to the PoC H-FABP test performed at ini-
tial presentation, but will be given access to all other
data. This kind of delayed-type reference standard using
an expert panel is considered a reasonable alterna-
tive, especially in a low-prevalence setting if the def-
inite reference standard (for example, serial troponin
measurements or coronary angiography) is reasonably
unavailable for reasons of patient risk, cost, etc. [44].
In cases where final diagnosis of our expert panel ap-
pears to be different from the clinical diagnosis made
by the treating clinicians, we will follow the diagnosis
made by our expert panel.
The definitions of cardiac ischaemic situations – ‘stable
angina’ (SA), ‘unstable angina’ (UA), ‘acute myocardial in-
farction’ (AMI) and ‘heart-related sudden death’ – will be
standardised for this study based on current literature and
have been settled during a panel discussion with two cardi-
ologists, one GP, an ethicist and two researchers before the
trial started. SA will be defined as angina pectoris occur-
ring in a patient in predictable situations for months, with-
out a recent change in severity or amount of exertion that
is needed for angina pectoris to occur, whereas UA will be
defined as new or altered chest pain due to ischaemia with-
out myocardial cell damage reaching a level where signifi-
cant changes in myocardial damage-markers can be
measured [45,46]. AMI will be defined according to the
third universal definition of AMI [27]. This definition is
mainly based on the combination of clinical evidence and a
rise or fall in biomarker values, preferably hsTn. Exact cut-
off values for hsTn will depend on the 99th percentile as is
widely accepted. Further judgement on whether STEMI
(ST-segment elevation myocardial infarction) or NSTEMI
(non-ST-segment elevation (non-Q wave) myocardial in-
farction) has occurred will depend on the presence of ST-
elevations on the ECG.
The classification ‘none of these’ will refer to com-
plaints that are caused by other than cardiac diseases,
or by cardiac, non-ischaemic diseases. Those conditions
can be described by ‘atypical thoracic complaints’ or,
when available, by the clinical diagnosis (e.g. ‘gastric re-
flux’, ‘pericarditis’, etc.). Acute death of identified cause
will refer to any case of death occurring in a patient that
meets the inclusion criteria for the study and dies after
diagnostic evaluation has reached a point where cause of
death can reasonably be determined, or death occurring
in a patient before evaluation is done but where post-
mortem research is performed to identify cause of death.
In all other cases of acute death, the outcome will be de-
fined as acute death of unidentified cause.
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The most important feature of the algorithm of signs
and symptoms combined with PoC H-FABP testing will
be to adequately categorise all patients as either positive
or negative for ACS. The ability of the algorithm to rule
in UA in the ACS group is important, since UA is a con-
dition that does not give a rise in biomarkers and diag-
nosis depends exclusively on signs and symptoms.
Primary outcome: using multivariate analysis of our
data, signs and symptoms that have diagnostic value in
an algorithm to predict or exclude ACS and AMI will
be identified. The primary outcome measures of the
study will be sensitivity, specificity, positive and nega-
tive predictive value of an algorithm of those relevant
signs and symptoms combined with PoC H-FABP test-
ing for ACS and AMI, in patients with thoracic com-
plaints of new onset in general practice. To determine
influence of sex, age, duration of the complaints, and
kidney function on clinical performance of H-FABP-
testing, subgroup analyses within our study population will
be performed [47,48].
Secondary outcome: an economic evaluation by means
of an incremental cost-effectiveness ratio (ICER) will be
performed. This evaluation will be performed by determin-
ation of the ratio between the difference in medical costs
and the difference in benefits between the two strategies
that are observed in this study, being the usual reference
policy of the GP and the reference policy that could be cre-
ated using a determined algorithm consisting of a clinical
score and PoC H-FABP-testing. The benefits will be de-
scribed as reduction in number of referred patients versus
missed diagnoses if the algorithm is used.
Data management
Data will be stored confidentially and anonymously on the
research computer. Researchers obtaining patient data
30 days after study inclusion will work with decoded data.
Afterwards, coding will be restored. All data will be held
for 15 years after closure of the study. Handling of personal
data will comply with the Dutch Personal Data Protection
Act and the Belgian privacy legislation (http://wetten.
overheid.nl/BWBR0011468/geldigheidsdatum_30-10-2013).
Collected blood samples will be preserved for a maximum
of 15 years. These samples will only be used for analyses
that could contribute to our current field of research.
Withdrawal or missing data
Should patients refuse informed consent after initial
agreement on inclusion, they will be withdrawn from the
study and their data abolished. If final diagnosis is im-
possible due to insufficient data, calculations will be
made artificially regarding all patients with missing data
as having an ACS, as well as regarding them as having
no cardiac ischaemic cause for their initial complaints.Sample size and power calculation
An incidence of ACS of 22% would generate 132 pa-
tients with ACS and 468 patients without ACS in a study
population of 600 patients. To create a usable algorithm
consisting of signs, symptoms and H-FABP, the sensitiv-
ity of this algorithm should reach 85-90% and specificity
should reach 80-85%. In a worst case scenario, where
sensitivity would be 85% and specificity would be 80%,
combined with the incidence of ACS of 22%, PPV of
the algorithm of signs, symptoms and H-FABP for ACS
would be 54% (95% C.I. 47-61%) and the NPV 95%
(95% C.I. 93-97%). These diagnostic values with their
95% C.I. would be of significant interest, since PPV based
on clinical judgment only is 22% and NPV is 95%. There-
fore, a sample size of 600 generates adequate precision to
find clinically relevant improvement of PPV, as compared
to the current situation, and NPV that is at least not
diminishing.
Statistical analyses
Receiver Operating Characteristic (ROC) curves have been
used in an earlier stage to find the optimal cut-off point of
the venous H-FABP-test [8]. Using 2 × 2 tables and multi-
variate analyses, including CART analysis, multiple logistic
regression, or both, the diagnostic value of the H-FABP-
test in combination with clinical findings for ACS and
AMI will be assessed [49,50]. Our analysis will result in
PPVs and NPVs, sensitivity and specificity and their 95%
confidence intervals. Additionally, C-statistics will be pre-
sented to quantify overall prediction quality of the models.
Ethical considerations
The outcome of the test will be subject to this diagnostic
study and can therefore have no clinical consequence on
the GP’s decision. Patients willing to take part in this
study will mainly be treated as usual. Only a finger prick
blood analysis for H-FABP will be added to the normal
procedure and venous blood sampling will be added in
patients that are not referred to secondary care facilities.
This study will be in agreement with the current version
of the WMA Declaration of Helsinki and will be in
accordance with the Dutch Medical Research Involving
Human Subjects Act (WMO, http://wetten.overheid.nl/
BWBR0009408/geldigheidsdatum_29-10-2013) [51]. An
independent expert will be available in both countries
throughout the study and contact data of this expert
will be given to all participating patients. This study
protocol has been approved by the ethical review board
of Maastricht University for the Netherlands and by the
ethical review board of KU Leuven for Belgium. Full re-
search procedures are registered on www.clinicaltrials.gov,
NCT01826994.
All GPs including patients for our study will have a li-
ability insurance themselves or via the centre they work
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ance covering damage to research subjects through injury
or death caused by the study, that becomes apparent
within 4 years after the end of the study.
Informed consent
In a short time window of only one consultation, inclu-
sion in our study and performance of the PoC H-FABP
test will take place. The majority of the procedure can
be categorized as regular care. Therefore the ethical re-
view board was asked to agree on asking oral consent
(Belgium) and short written consent (The Netherlands)
from patients for taking the PoC H-FABP-test and (if
required) the venous blood sample by the GP on initial
consultation. This short content contains the four basic
principles as stated in article six of the Dutch law for
scientific research concerning humans. Subsequently,
within one to seven days from initial consultation, pa-
tients will be given the opportunity for complete writ-
ten informed consent after having read an information
letter at a more convenient moment. Patients may also
decide to withdraw their consent then or at any time
thereafter. Only patients who return a written short
and complete informed consent will be included in our
study.
Incentives
All GPs will receive €40 per included patient as a com-
pensation for their extra workload.
Publication policy
All data, results of analyses and conclusions by the study
team, either favourable or unfavourable to using PoC
H-FABP testing will be disclosed by offering our work for
publication in (a) medical journal(s). Our report will follow
the international STROBE guideline.
Discussion
Our study, which commenced in November 2013, will
focus on deriving factors to be included in an algorithm
of signs and symptoms combined with PoC H-FABP
testing (stage 2 of the aforementioned stages of Stiell
and Wells) [42]. All criteria for a methodologically correct
stage 2 (definition of outcomes and predictor variables,
generalisability of subject selection, several statistical and
methodological demands) are present in this study, except
the inter-observer reliability for the clinical findings, which
is difficult to measure in the acute setting in primary care.
This study, and subsequent studies aiming to validate, im-
plement and calculate cost-effectiveness (stages 3–6 of
Stiell and Wells) in a new clinical setting will possibly en-
able formulation of a clinical decision rule meeting the
current criteria for an effective decision rule [52]. The
focus will be on substantially changing clinical behaviourand thus safely reducing the number of referred patients
by GPs to secondary care facilities without underlying
ACS. An improved triage of patients presenting with chest
complaints possibly due to ACS can lead to a substantial
cost reduction.
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